will have a choice of attending more than 26
educational sessions to learn how innovators are advancing clinical care
and enhancing their financial strength by incorporating the latest
molecular imaging techniques in tandem with emerging molecular diagnostics.
Industry pioneers will speak about evolving changes in R&D, the discovery
of new medicines, effective policies to translate these discoveries into
better outcomes for patients, resulting treatments that improve healthcare,
and new business strategies to advance the field of personalized medicine.
Continuing Education Units (CEU's) are provided by the American Association
of Clinical Chemistry (AACC).
"Healthcare is evolving, entering a new era, one created through the
marriage of in vivo and in vitro diagnostics, arming clinicians with the
tools that enable early intervention and treatment in a way that improves
clinical efficiencies, effectiveness and outcomes," said Thomas Miller,
CEO, Workflow and Solutions Division, Siemens Healthcare. "We are ushering
in the era of personalized medicine, moving the practice of medicine from
the disease- centric to the knowledge-driven, patient-centric approach. For
all of us who care passionately about this -- pathologists, radiologists
and healthcare IT executives -- the Summit will deliver the latest
information defining the next generation of integrated diagnostic and
clinical services."
The Molecular Summit will feature case studies involving the delivery
of molecular imaging and molecular diagnostics services, particularly where
collaboration is occurring between radiology, pathology, and informatics to
integrate molecular imaging with relevant molecular diagnostics services.
"Alert physicians involved in imaging and molecular diagnostics know
these technology advances are already breaking down traditional specialty
silos," said Robert L. Michel, editor, The Dark Report. "The Molecular
Summit brings together early adopters who will share their pr
'/>"/>
SOURCE Siemens Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 Related biology technology :1.
Varian, Inc. Reports First Quarter 2008 Results2.
PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results3.
Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis4.
VNUS Medical Technologies to Report Fourth-Quarter 2007 Results and Webcast Teleconference on February 75.
Quest Diagnostics Sets New Date to Report Fourth Quarter and Full Year 2007 Results6.
Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues7.
Pharmasset Reports Fiscal Year End 2007 Financial Results8.
Avitar Reports Fourth Quarter and Fiscal Year 2007 Financial Results9.
Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine10.
Imagenetix Reports Results of Offer to Extend Warrants11.
Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board